Enanta Pharmaceuticals Inc (ENTA) stock
ENTANasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026Score 2/3018% above fair value
$10.99−0.21 (-1.87%)
Close on Nov 13, 2026Market cap $320.09MP/E –Yield –
Enanta Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Enanta Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -90.0%. For fiscal 2025 it was -130.7%, against -179.9% the year before. The highest annual figure on record is 77.2% in fiscal 2015.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -130.7% | +49.3 |
| FY2024 | Sep 30, 2024 | -179.9% | −6.7 |
| FY2023 | Sep 30, 2023 | -173.2% | −29.5 |
| FY2022 | Sep 30, 2022 | -143.7% | −30.9 |
| FY2021 | Sep 30, 2021 | -112.9% | −78.9 |
| FY2020 | Sep 30, 2020 | -34.0% | −51.9 |
| FY2019 | Sep 30, 2019 | 17.9% | −24.8 |
| FY2018 | Sep 30, 2018 | 42.7% | +18.8 |
| FY2017 | Sep 30, 2017 | 23.9% | −11.0 |
| FY2016 | Sep 30, 2016 | 34.9% | −42.2 |
| FY2015 | Sep 30, 2015 | 77.2% | +37.4 |
| FY2014 | Sep 30, 2014 | 39.8% | +11.6 |
| FY2013 | Sep 30, 2013 | 28.2% | −22.9 |
| FY2012 | Sep 30, 2012 | 51.0% | −9.4 |
| FY2011 | Sep 30, 2011 | 60.4% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -120.0% | +18.8 |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -69.1% | +135.3 |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -60.5% | +74.1 |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -121.6% | +70.6 |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -138.8% | +55.0 |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -204.4% | −40.5 |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -134.6% | +59.8 |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -192.1% | +29.6 |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -193.8% | −66.5 |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -163.9% | −30.8 |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -194.3% | −27.3 |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -221.7% | −40.9 |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -127.3% | −17.3 |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -133.1% | +9.9 |
| Q3 FY2022CQ2 2022 | Jun 30, 2022 | -167.1% | −10.5 |
| Q2 FY2022CQ1 2022 | Mar 31, 2022 | -180.8% | −33.3 |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -110.0% | −71.2 |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -143.1% | −59.3 |
| Q3 FY2021CQ2 2021 | Jun 30, 2021 | -156.5% | −34.0 |
| Q2 FY2021CQ1 2021 | Mar 31, 2021 | -147.5% | −104.5 |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -38.7% | −63.2 |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -83.7% | −96.2 |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -122.5% | −131.0 |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -43.0% | −39.7 |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | 24.5% | −15.4 |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | 12.5% | −38.7 |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | 8.5% | −31.1 |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -3.3% | −41.6 |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | 39.9% | +2.1 |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | 51.3% | −20.2 |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | 39.5% | +214.3 |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | 38.3% | +144.4 |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | 37.7% | +105.4 |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | 71.5% | +95.6 |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -174.8% | −167.0 |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -106.1% | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -67.6% | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -24.1% | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -7.8% | – |
See a number that looks wrong?